| Description | The tumour necrosis factor (TNF) receptor (TNFR) superfamily comprises more than 20 type-I transmembrane proteins. Family members are defined based on similarity in their extracellular domain - a region that contains many cysteine residues arranged in a specific repetitive pattern [ ]. The cysteines allow formation of an extended rod-like structure, responsible for ligand binding [].Upon receptor activation, different intracellular signalling complexes are assembled for different members of the TNFR superfamily, depending on their intracellular domains and sequences [ ]. Activation of TNFRs can therefore induce a range of disparate effects, including cell proliferation, differentiation, survival, or apoptotic cell death, depending upon the receptor involved [].TNFRs are widely distributed and play important roles in many crucial biological processes, such as lymphoid and neuronal development, innate and adaptive immunity, and maintenance of cellular homeostasis [ ]. Drugs that manipulate their signalling have potential roles in the prevention and treatment of many diseases, such as viral infections, coronary heart disease, transplant rejection, and immune disease [ ].This entry includes the TNF receptors 13C and 17. TNFR 17 acts as a receptor for both a proliferation-inducing ligand (APRIL) and B cell-activating factor (BAFF, also called BLyS or TALL-I) [ , ]. It is preferentially expressed by mature B-cells, suggesting a that it is involved in cell survival and proliferation. It has been demonstrated that it acts through the activation of NF-kappa-B and JNK pathways []. TNFR 13C is a B-cell receptor specific for BAFF and it promotes the mature B-cells survival and response []. | Name | Tumor necrosis factor receptor 13C/17 |
| Short Name | TNFR_13C/17 | Type | Family |
Powered by
Have you tried our InterMine mobile apps?
and interoperation is funded by 
